Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. reported significant financial growth, with Cell Processing revenue reaching $25.3 million, marking a 33% year-over-year increase, and total revenue for 3Q25 at $28.1 million, reflecting a 31% year-over-year growth, which surpassed projections. Additionally, the company achieved net income of $0.6 million, or $0.01 per share, against expectations of a loss, indicating improved profitability. Management anticipates a gross margin in the low-60% range for 2025, along with a reduction in net loss and expansion of adjusted EBITDA margin, enhancing the company's financial outlook.

Bears say

BioLife Solutions faces several challenges that contribute to a negative outlook, including the risk of lower-than-projected growth in its product offerings and potential difficulties in acquiring new customers. Revenue guidance for FY2025 has been revised downwards, with an $8 million reduction in expectations leading to anticipated revenues of $95.0-96.0 million, which reflects a decline in growth momentum at 27-29% year-over-year. Additionally, the company remains susceptible to fluctuations in sales within emerging markets, foreign exchange rates, and potential dilution risks, which could further impair its financial stability.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.